Evogene Schedules First Quarter 2025 Financial Results Release
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a computational biology company focused on life-science product discovery and development, has announced it will release its Q1 2025 financial results on Wednesday, May 21, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time) on the same day. Interested participants can register for the conference call through the company's provided link. The conference recording will be made available on Evogene's website in the following days.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), un'azienda di biologia computazionale specializzata nella scoperta e sviluppo di prodotti per le scienze della vita, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 il mercoledì 21 maggio 2025. La società terrà una conference call per discutere i risultati alle 9:00 AM ET (16:00 ora di Israele) dello stesso giorno. Gli interessati possono registrarsi alla conference call tramite il link fornito dall'azienda. La registrazione della conferenza sarà disponibile sul sito web di Evogene nei giorni successivi.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), una empresa de biología computacional enfocada en el descubrimiento y desarrollo de productos para ciencias de la vida, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el miércoles 21 de mayo de 2025. La compañía realizará una llamada conferencia para discutir los resultados a las 9:00 AM ET (16:00 hora de Israel) ese mismo día. Los interesados pueden registrarse para la llamada a través del enlace proporcionado por la empresa. La grabación de la conferencia estará disponible en el sitio web de Evogene en los días siguientes.
Evogene Ltd. (나스닥: EVGN, TASE: EVGN)는 생명과학 제품 발견 및 개발에 중점을 둔 계산생물학 회사로서, 2025년 1분기 재무 결과를 2025년 5월 21일 수요일에 발표할 예정입니다. 회사는 같은 날 동부 표준시 오전 9시 (이스라엘 시간 오후 4시)에 결과를 논의하는 컨퍼런스 콜을 진행합니다. 관심 있는 참가자는 회사가 제공한 링크를 통해 컨퍼런스 콜에 등록할 수 있습니다. 컨퍼런스 녹음은 이후 며칠 내에 Evogene 웹사이트에서 제공될 예정입니다.
Evogene Ltd. (Nasdaq : EVGN, TASE : EVGN), une société de biologie computationnelle spécialisée dans la découverte et le développement de produits en sciences de la vie, a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le mercredi 21 mai 2025. La société tiendra une conférence téléphonique pour discuter des résultats à 9h00 ET (16h00 heure d'Israël) le même jour. Les participants intéressés peuvent s'inscrire à la conférence via le lien fourni par la société. L'enregistrement de la conférence sera disponible sur le site web d'Evogene dans les jours qui suivront.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), ein Unternehmen für computergestützte Biologie mit Fokus auf die Entdeckung und Entwicklung von Produkten im Bereich der Lebenswissenschaften, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Mittwoch, den 21. Mai 2025 zu veröffentlichen. Das Unternehmen wird am selben Tag um 9:00 Uhr ET (16:00 Uhr israelische Zeit) eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Interessierte Teilnehmer können sich über den bereitgestellten Link des Unternehmens für die Telefonkonferenz anmelden. Die Aufzeichnung der Konferenz wird in den folgenden Tagen auf der Website von Evogene verfügbar sein.
- None.
- None.
Zoom conference call scheduled for May 21, 2025, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To join the conference, please register in advance:
https://www.veidan-conferenceing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
- Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
- Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
- Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.
For more information, please visit: www.evogene.com.
Contact
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-first-quarter-2025-financial-results-release-302449812.html
SOURCE Evogene
FAQ
When will Evogene (EVGN) release its Q1 2025 earnings?
What time is Evogene's Q1 2025 earnings call?
How can I join Evogene's Q1 2025 earnings call?
Will Evogene's Q1 2025 earnings call be available for replay?
